CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| EAA181 | ECOG-ACRIN | Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended For Early Autologous Transplantation | Adult CIRB - Late Phase Emphasis | Available to Open |
| S0023 | SWOG | A Phase III Trial of Cisplatin/Etoposide/ Radiotherapy with Consolidation Docetaxel Followed by Maintenance Therapy with ZD1839 or Placebo in Patients with Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer | Adult CIRB - Late Phase Emphasis | Completed |
| S1937 | SWOG | A Phase III Randomized Trial of Eribulin (NSC #707389) with or without Gemcitabine versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy | Adult CIRB - Late Phase Emphasis | Available to Open |
| S1404 | SWOG | A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma | Adult CIRB - Late Phase Emphasis | Available to Open |
| E4A03 | ECOG | A Randomized Phase III Study of CC-5013 Plus Dexamethasone Versus CC-5013 Plus Low Dose Dexamethasone in Multiple Myeloma with Thalidomide Plus Dexamethasone Salvage Therapy for Non-Responders | Adult CIRB - Late Phase Emphasis | Available to Open |
| A091903 | Alliance | A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma | Adult CIRB - Late Phase Emphasis | Available to Open |
| A021602 | Alliance | Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET) | Adult CIRB - Late Phase Emphasis | Available to Open |
| CALGB-10201 | CALGB | A Phase III Study of Daunorubicin and Cytarabine +\- G3139 (GenasenseTM; Oblimersen Sodium; NSC #683428; IND #58842); A BCL2 Antisense Oligodeoxynucleotide; in Previously Untreated Patients with Acute Myeloid Leukemia (AML) > 60 Years | Adult CIRB - Late Phase Emphasis | Completed |
| GOG-0277 | GOG | A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NCS# 123127) versus Observation for Uterus-Limited; High Grade Uterine Leiomyosarcoma | Adult CIRB - Late Phase Emphasis | Completed |
| NRG-LU006 | NRG | Phase III Randomized Trial of Pleurectomy/Decortication Plus Chemotherapy with or without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM) | Adult CIRB - Late Phase Emphasis | Available to Open |